The IL23R gene encodes the interleukin-23 receptor, a key player in immune regulation that pairs with IL12RB1 to form the functional receptor for IL-23, a pro-inflammatory cytokine. IL-23 drives the differentiation and survival of Th17 cells¹¹ IL-23 drives the differentiation and survival of Th17 cells
immune cells that produce IL-17 and contribute to chronic inflammation. The R381Q variant (rs11209026) is one of the most protective genetic variants ever identified for inflammatory bowel disease, reducing risk for Crohn's disease by more than 50% and ulcerative colitis by about 30-50%. This single amino acid change — arginine to glutamine at position 381 — fundamentally alters how your immune system responds to inflammatory signals.

The Mechanism

The R381Q variant is a [missense mutation | changes one amino acid in the protein sequence] that replaces arginine with glutamine in the cytoplasmic tail of the IL-23 receptor, between the transmembrane domain and the JAK2 binding site. This arginine is absolutely conserved across species²² absolutely conserved across species
present in the same position in mice, rats, and other mammals, indicating its critical importance for normal receptor function. The R381Q variant creates a loss-of-function receptor through multiple mechanisms. First, it alters mRNA splicing by reducing binding of the SF2 splicing enhancer³³ alters mRNA splicing by reducing binding of the SF2 splicing enhancer
promoting exon 9 skipping, which increases expression of a soluble IL-23R isoform that acts as a decoy receptor, soaking up IL-23 before it can activate cells. Second, the variant reduces surface expression of the receptor⁴⁴ reduces surface expression of the receptor
through impaired protein stability and trafficking, meaning fewer functional receptors reach the cell membrane. Third, even when the R381Q receptor does reach the surface, it shows reduced IL-23-induced STAT3 phosphorylation⁵⁵ reduced IL-23-induced STAT3 phosphorylation
weaker downstream signaling, blunting the inflammatory cascade.

The Evidence

The protective effect of R381Q was first discovered in a landmark 2006 genome-wide association study⁶⁶ landmark 2006 genome-wide association study
Duerr et al., A genome-wide association study identifies IL23R as an inflammatory bowel disease gene that scanned the genomes of 547 patients with ileal Crohn's disease. The A allele (encoding glutamine) was found in 7% of healthy controls but only 1.9% of Crohn's disease patients, yielding an odds ratio of 0.45 for disease protection. This has been replicated in dozens of independent cohorts⁷⁷ replicated in dozens of independent cohorts
representing tens of thousands of individuals. A 2019 meta-analysis of 41 studies encompassing 13,803 Crohn's disease patients, 5,876 ulcerative colitis patients, and over 27,000 controls confirmed the variant as a protective factor against IBD. The protective effect extends beyond IBD: R381Q also reduces risk for psoriasis (OR 0.49)⁸⁸ reduces risk for psoriasis (OR 0.49)
Capon et al., Sequence variants in the genes for the interleukin-23 receptor, ankylosing spondylitis, and other immune-mediated diseases that involve the IL-23/Th17 pathway.

Functional studies have clarified why the variant is protective. Primary T cells from R381Q carriers⁹⁹ Primary T cells from R381Q carriers
both heterozygotes and homozygotes show reduced surface IL-23R expression and decreased IL-23-induced STAT3 phosphorylation, translating to less IL-17 and IL-22 production — key inflammatory cytokines in the gut. Macrophages from R381Q carriers¹⁰¹⁰ Macrophages from R381Q carriers
also show reduced IL-23-dependent bacterial clearance, which may seem paradoxical given the protective effect, but likely reflects a trade-off: slightly reduced antimicrobial capacity in exchange for dramatically lower chronic inflammation. The net effect is protective, as excessive Th17 responses cause more damage than benefit in the context of IBD.

Practical Implications

If you carry one or two copies of the A allele at rs11209026, your baseline risk for inflammatory bowel disease is substantially lower than the general population. This doesn't mean you're immune — environmental factors, diet, gut microbiome composition, stress, and other genetic variants all contribute — but your genetic predisposition is significantly more favorable. For Crohn's disease specifically, each copy of the A allele reduces risk by about 50-60%, meaning AA homozygotes have approximately 70-75% lower risk than GG individuals.

The variant's protective effect is mediated through the IL-23/Th17 pathway, which is now a major therapeutic target in IBD. Biologics targeting IL-12/IL-23 (ustekinumab) and IL-23 specifically (risankizumab, guselkumab)¹¹¹¹ Biologics targeting IL-12/IL-23 (ustekinumab) and IL-23 specifically (risankizumab, guselkumab)
have shown efficacy in Crohn's disease and ulcerative colitis, essentially mimicking the effect of the R381Q variant pharmacologically. If you're GG (standard risk) and develop IBD, you may be a particularly good candidate for IL-23-targeted therapies, as you lack the natural protection the A allele provides. Conversely, if you're AA and still develop IBD, other pathways are likely more important in your disease, and IL-23 blockade may be less effective.

Beyond IBD, the R381Q variant's effects on immune regulation suggest broader implications for autoimmune disease risk. The IL-23/Th17 axis is implicated in psoriasis, psoriatic arthritis, ankylosing spondylitis, rheumatoid arthritis, and multiple sclerosis. Carriers of the A allele may have modestly reduced risk for these conditions as well.

Interactions

IL23R sits at a critical node in the inflammatory cascade, downstream of pattern recognition receptors (like NOD2, another major Crohn's disease gene) and upstream of Th17 cell differentiation. The protective effect of IL23R R381Q appears to be independent of other IBD risk variants — it's not simply tagging a protective haplotype but is itself the causal variant. Studies have found no epistatic interaction between IL23R and CARD15 (NOD2)¹²¹² no epistatic interaction between IL23R and CARD15 (NOD2)
the two genes act independently, meaning their effects are additive rather than synergistic. However, given that both genes feed into overlapping inflammatory pathways, individuals with favorable variants in both genes (e.g., IL23R R381Q plus wild-type NOD2) would have the lowest IBD risk, while those with risk variants in both would have compounded susceptibility.

The IL-23 receptor is also expressed on innate lymphoid cells, NK cells, and macrophages, not just T cells. The R381Q variant affects all these cell types, contributing to its broad protective effect across multiple immune-mediated diseases. The variant's impact on macrophage function — reducing IL-23-dependent bacterial clearance — raises interesting questions about infection susceptibility, though no increased infection risk has been documented in R381Q carriers¹³¹³ no increased infection risk has been documented in R381Q carriers
likely because multiple redundant antimicrobial pathways exist.

Your leptin receptor (LEPR) gene encodes the protein that receives signals from leptin¹¹ leptin
The "satiety hormone" produced by fat cells proportional to energy stores, the hormone your fat cells release to tell your brain you've had enough to eat. The Q223R variant (rs1137101) is one of the most studied LEPR polymorphisms worldwide — an A-to-G transition at codon 223 that changes a neutral glutamine to a positively charged arginine in the extracellular leptin-binding domain of the receptor. Carriers of the G allele (Arginine-223) show higher circulating leptin levels despite comparable or greater body fat — a hallmark of leptin resistance²² a hallmark of leptin resistance
When leptin rises but fails to suppress appetite, the body compensates by producing more leptin rather than responding to it.

The Mechanism

The Q223R substitution sits in the cytokine receptor homology 1 (CRH1) domain of the leptin receptor, specifically in the extracellular loop connecting the CRH and fibronectin type III domains where leptin physically contacts its receptor. Glutamine at position 223 is neutral; arginine is positively charged. This charge change alters the local electrostatic environment of the binding interface.

In vitro studies have shown mixed results. The most rigorous functional study — a 2009 paper by Stratigopoulos et al.³³ a 2009 paper by Stratigopoulos et al.
Functional consequences of the human leptin receptor Q223R transversion. PubMed 18997673 — used mice expressing humanized LEPR alleles and found no differences in body weight, body composition, energy expenditure, or leptin-induced STAT3 phosphorylation between Q223 and R223 animals. This casts doubt on a direct mechanistic effect at physiological leptin concentrations. However, the R223 allele may affect receptor trafficking, surface expression kinetics, or downstream signaling efficiency under conditions of chronic leptin exposure or energy excess that differ from controlled laboratory settings.

The most reproducible finding in human carriers is elevated circulating leptin levels⁴⁴ elevated circulating leptin levels
GG carriers consistently show higher plasma leptin in proportion to their adiposity. This hyperleptinemia without proportional appetite suppression is a defining feature of leptin resistance — the body upregulates leptin production in an attempt to overcome reduced receptor responsiveness. Whether Q223R causes leptin resistance or is merely in linkage disequilibrium with a truly functional variant remains debated.

The Evidence

A 2024 meta-analysis of 39 studies⁵⁵ 2024 meta-analysis of 39 studies
6,099 obesity cases and 6,711 controls across Asian and Caucasian populations found significant associations across all genetic models for the G allele and obesity: homozygous model (GG vs AA: OR=1.39, 95% CI=1.12–1.73, p=0.003), dominant model (AG/GG vs AA: OR=1.28, p=0.001), and allelic model (G vs A: OR=1.19, p=0.002). Importantly, the association was significant in both Asian and Caucasian subgroups separately, reducing concerns about population stratification confounding.

A Sri Lankan cohort study of overweight and obese adults⁶⁶ Sri Lankan cohort study of overweight and obese adults
Jayawardena et al. BMC Research Notes, 2020 found GG carriers had 1.3 kg/m² greater BMI (p=0.04) and 3.8 cm greater waist circumference (p=0.03) compared to AA carriers among overweight subjects. The association was not seen in normal-weight individuals, suggesting the variant's effects emerge primarily in the context of energy excess.

Beyond obesity, the G allele has been linked to insulin resistance and metabolic syndrome⁷⁷ insulin resistance and metabolic syndrome
Gln223Arg associated with HOMA-IR and hyperglycemia in Kyrgyz population: OR=1.83, 95% CI 1.03–3.24. A meta-analysis of PCOS studies⁸⁸ meta-analysis of PCOS studies
rs1137101 significantly associated with PCOS susceptibility in Asian populations found the G allele increased polycystic ovary syndrome risk, consistent with leptin's known role in hypothalamic-pituitary-gonadal axis regulation. In girls, the RR genotype was associated with earlier menarche⁹⁹ RR genotype was associated with earlier menarche
11.5 years for RR vs 12.0 years for QQ, p<0.05, suggesting the leptin receptor variant influences pubertal timing.

The G allele frequency varies dramatically by ancestry: roughly 88% in East Asian populations (where GG is the majority genotype), 56% in Africans, 47–49% in Europeans and South Asians, and 44% in Latinos. This high East Asian frequency means GG is the modal genotype in East Asian populations, while carrying different population-attributable risk across ancestry groups.

Practical Actions

The variant's effects on obesity susceptibility appear most pronounced in environments of chronic caloric excess. High-protein diets are particularly relevant for LEPR variants: protein is the macronutrient with the strongest leptin-sensitizing effect at the hypothalamic level — studies show dietary protein at 25–30% of calories reduces spontaneous energy intake by ~400 kcal/day¹⁰¹⁰ studies show dietary protein at 25–30% of calories reduces spontaneous energy intake by ~400 kcal/day
Weigle et al. Am J Clin Nutr 2005 by amplifying leptin's satiety signal in the arcuate nucleus, independent of changes in leptin levels themselves.

Omega-3 fatty acids (EPA and DHA) are worth highlighting for G allele carriers: PUFA status interacts with leptin receptor variants to modify metabolic syndrome and insulin resistance risk¹¹¹¹ PUFA status interacts with leptin receptor variants to modify metabolic syndrome and insulin resistance risk
Low n-3 plus high n-6 PUFA status amplifies metabolic syndrome risk; high n-3 abolishes genetic risk. A favorable omega-3 status may partially compensate for the genetic predisposition.

Leptin follows a circadian rhythm, peaking at night. Eating late into the evening misaligns feeding with this rhythm, compounding leptin resistance. Time-restricted eating confined to daylight hours can help preserve the normal leptin secretion pattern.

Interactions

The three most studied LEPR coding variants — K109R (rs1137100), Q223R (rs1137101), and K656N (rs1805094) — occur in partial linkage disequilibrium¹²¹² partial linkage disequilibrium
They're inherited together more often than expected by chance, but not perfectly correlated. Some studies suggest compound effects from carrying multiple LEPR variants. rs1137100 (K109R) has been studied in relation to metabolic phenotypes and may amplify the Q223R effect when both are present; this would merit a compound action combining GG at rs1137101 with the rs1137100 risk genotype if the individual carries both.

Leptin signaling is also influenced by LEP rs7799039 (G-2548A)¹³¹³ LEP rs7799039 (G-2548A)
Encodes more leptin production; carries separate obesity risk, which affects leptin gene expression levels. Individuals carrying both higher-leptin LEP variants and reduced-responsiveness LEPR variants would be expected to have greater leptin resistance than either alone — another candidate compound interaction.

Finally, leptin cross-talks with the hypothalamic-pituitary axis governing reproductive hormones¹⁴¹⁴ hypothalamic-pituitary axis governing reproductive hormones
Leptin signals the hypothalamus that energy stores are sufficient for reproduction; impaired signaling delays or disrupts this axis. G allele carriers, particularly women, may experience leptin-mediated effects on reproductive timing, menstrual regularity, and PCOS risk.

The HIF1A gene encodes hypoxia-inducible factor 1-alpha¹¹ hypoxia-inducible factor 1-alpha
The oxygen-sensing subunit of a transcription factor that activates >100 genes controlling red blood cell production, blood vessel growth, and metabolic adaptation, the master regulator of how your cells respond to low oxygen. When oxygen drops — during intense exercise, at altitude, or in poorly perfused tissues — HIF-1α triggers a coordinated response: it ramps up erythropoietin (EPO)²² erythropoietin (EPO)
The hormone that stimulates red blood cell production in bone marrow production to boost oxygen carrying capacity, activates VEGF³³ VEGF
Vascular endothelial growth factor, the primary signal for new blood vessel formation to grow new blood vessels, and shifts metabolism toward anaerobic glycolysis⁴⁴ anaerobic glycolysis
ATP production without oxygen, less efficient but faster than oxidative phosphorylation for rapid energy production. The Pro582Ser polymorphism (rs11549465), a C-to-T change in exon 12, replaces proline with serine at position 582 in the protein's oxygen-dependent degradation domain⁵⁵ oxygen-dependent degradation domain
The region where oxygen-sensing enzymes hydroxylate specific prolines, marking HIF-1α for destruction under normal oxygen. About 10% of Europeans and 12% of South Asians carry at least one copy of the Ser (T) allele.

The Mechanism

Under normal oxygen conditions, prolyl hydroxylase enzymes⁶⁶ prolyl hydroxylase enzymes
PHD2 and PHD3 hydroxylate Pro402 and Pro564, enabling von Hippel-Lindau protein binding rapidly degrade HIF-1α by hydroxylating two critical proline residues (Pro402 and Pro564), enabling recognition by the von Hippel-Lindau protein⁷⁷ von Hippel-Lindau protein
VHL binds hydroxylated HIF-1α and targets it for ubiquitin-mediated destruction, keeping baseline HIF levels low, which tags it for destruction. When oxygen drops, these hydroxylases become inactive, HIF-1α stabilizes, moves to the nucleus, dimerizes with HIF-1β, and activates its target genes. The Pro582Ser change sits in this degradation domain, near the hydroxylation sites. Despite early concerns, laboratory studies⁸⁸ laboratory studies
Tanimoto et al. showed Pro582 hydroxylation assays revealed no effect on Pro564 hydroxylation or VHL binding confirmed it doesn't impair the normal hydroxylation-degradation process. The functional difference appears more subtle: the Ser582 variant may alter HIF-1α protein stability or transcriptional activity under specific physiological conditions, particularly during prolonged or repeated hypoxic exposure, though the exact mechanism remains debated.

The Evidence — Elite Endurance

The landmark 2010 study⁹⁹ landmark 2010 study
Döring F et al. A common haplotype and the Pro582Ser polymorphism of HIF1A in elite endurance athletes. J Appl Physiol, 2010 by Döring and colleagues examined 316 elite male endurance athletes (average VO₂max: 79 ml/kg/min) versus 304 sedentary controls. Pro/Pro homozygotes were significantly overrepresented in athletes: 84% versus 75% in controls. The odds ratio of being an elite endurance athlete for Pro/Pro individuals was 1.77 (95% CI: 1.18-2.67, p=0.006) compared to Ser carriers. A specific HIF1A haplotype (15% frequency) including the Pro allele and the minor A allele of rs17099207 showed an even stronger association: OR 2.37 (95% CI: 1.21-4.66, p=0.012). This suggests the Pro582 allele may support the prolonged, adaptive hypoxic responses required for elite endurance performance — possibly through more efficient erythropoiesis, enhanced capillary density, or optimized mitochondrial function in response to training.

The Evidence — Injury Risk

In a surprising twist, the same Pro/Pro genotype that confers endurance advantages appears to increase injury vulnerability. A six-season prospective study¹⁰¹⁰ six-season prospective study
Larruskain J et al. Genetic Variants and Hamstring Injury in Soccer. Med Sci Sports Exerc, 2018 of 107 elite male soccer players found that CC (Pro/Pro) individuals had a hazard ratio of 2.08 (95% CI: 1.00-4.29) for hamstring injuries compared to CT heterozygotes. The mechanism is unclear but may involve altered tissue remodeling or vascular response to mechanical loading. HIF-1α is induced by mechanical stress and plays a role in matrix remodeling and myogenesis¹¹¹¹ matrix remodeling and myogenesis
Collagen synthesis, extracellular matrix reorganization, and satellite cell activation during muscle repair. If the Pro/Pro variant modulates these repair processes differently, it could affect tissue resilience under the repeated eccentric loads of sprint-heavy sports like soccer. This doesn't diminish the endurance benefits, but it suggests Pro/Pro athletes in explosive sports may need more attention to injury prevention.

Gene-Gene Interactions

HIF1A doesn't act alone. A 2009 study¹²¹² 2009 study
Ahmetov II et al. Is the interaction between HIF1A P582S and ACTN3 R577X determinant for power/sprint performance? Eur J Appl Physiol, 2009 examined the interaction between HIF1A Pro582Ser and ACTN3 R577X in Russian athletes. The combination of HIF1A Pro/Pro + ACTN3 R/R yielded an odds ratio of 2.25 for being a sprinter, significantly higher than either variant alone. This makes biological sense: ACTN3 determines fast-twitch fiber presence while HIF1A controls the metabolic and vascular environment those fibers operate in. For sport genetics, this is a reminder that single variants tell part of the story; interactions matter.

Other HIF1A polymorphisms are also worth noting. The rs2057482 variant¹³¹³ rs2057482 variant
Located in the 3' untranslated region, possibly affecting microRNA binding and mRNA stability has been associated with cancer risk and cardiovascular disease in some populations. The rs17099207 SNP forms a haplotype with Pro582Ser that shows stronger endurance associations than either variant individually.

Practical Actions — Training and Adaptation

The Pro/Pro genotype suggests a robust hypoxic response system. These individuals may benefit more from altitude training camps or simulated altitude methods¹⁴¹⁴ simulated altitude methods
Sleep-high-train-low protocols, hypoxic tents, or intermittent hypoxic exposure. However, the evidence for hypoxia training benefits is strongest when combined with adequate iron status. HIF-1α activation stimulates EPO, which drives erythropoiesis — but without sufficient iron, ferritin stores¹⁵¹⁵ ferritin stores
The storage form of iron; levels <30 µg/L in athletes may limit training adaptations deplete rapidly and the adaptive response stalls. Studies show¹⁶¹⁶ Studies show
Iron-deficient athletes at altitude fail to increase hemoglobin and miss performance gains that iron insufficiency blunts the erythropoietic response to altitude.

Dietary nitrate supplementation¹⁷¹⁷ Dietary nitrate supplementation
Found in beetroot juice, arugula, spinach; converted to nitric oxide particularly under hypoxic/acidic conditions — via beetroot juice or leafy greens — may complement HIF-mediated adaptations by enhancing nitric oxide availability¹⁸¹⁸ nitric oxide availability
Improves blood flow, mitochondrial efficiency, and muscle contractility during hypoxia. While meta-analyses¹⁹¹⁹ meta-analyses
Ergogenic effect mainly in recreationally active individuals, not elite athletes show modest or no benefit in already-elite athletes, recreational and sub-elite athletes may see improvements in time-to-exhaustion and high-intensity performance.

For Pro/Pro athletes in explosive sports (soccer, rugby, basketball), the hamstring injury data warrants attention to eccentric loading protocols²⁰²⁰ eccentric loading protocols
Gradual introduction of high-force lengthening contractions with adequate recovery, adequate recovery, and possibly proactive hamstring strengthening (Nordic curls, Romanian deadlifts). The injury mechanism is speculative but suggests these athletes might need longer adaptation periods when increasing sprint or plyometric volume.

Practical Actions — Beyond Sports

HIF1A variants have been studied beyond athletics. The Pro582Ser polymorphism has been associated with cancer susceptibility²¹²¹ cancer susceptibility
Meta-analyses show population-specific effects, higher risk in Asians, lower risk in Caucasians for certain cancers in meta-analyses, though results are inconsistent and population-dependent. A 2014 meta-analysis of 49 studies found associations with digestive tract cancers, particularly in Asian populations. It's also been linked to diabetic retinopathy²²²² diabetic retinopathy
Possibly through dysregulated angiogenesis and inflammatory markers in the retina in patients with type 2 diabetes. These associations don't imply causality and shouldn't trigger alarm, but they do highlight HIF-1α's role in processes beyond oxygen sensing — including tumor angiogenesis and chronic disease progression.

Interactions

The HIF1A Pro582Ser variant interacts with ACTN3 R577X (rs1815739) to influence sprint and power performance. Individuals with both HIF1A Pro/Pro and ACTN3 R/R show significantly higher odds of being elite sprinters than those with either genotype alone (OR 2.25). This represents a gene-gene interaction where the metabolic and vascular advantages of Pro/Pro combine with the fast-twitch muscle advantage of ACTN3 R/R. Such interactions are important in sports genetics and suggest that for athletes, the HIF1A genotype should be interpreted alongside muscle fiber type genetics.

The rs17099207 SNP forms a haplotype with Pro582Ser that amplifies the endurance association. The HIF1A rs2057482 variant has been linked to cardiovascular disease risk and may interact with Pro582Ser in determining overall cardiovascular adaptation capacity, though direct interaction studies are lacking.

Your mitochondria are not just energy factories — they are also the primary site of cellular aging. Every time they burn fuel, they generate reactive oxygen species ¹¹ Reactive oxygen species (ROS) are chemically reactive molecules containing oxygen, such as superoxide and hydrogen peroxide, that damage DNA, proteins, and membranes if not rapidly neutralized that gradually damage the proteins, lipids, and DNA inside the cell. The gene SIRT3 encodes the master regulator of mitochondrial health: a NAD⁺-dependent deacetylase ²² A deacetylase removes acetyl groups from target proteins, changing their activity — analogous to flipping molecular on/off switches that controls dozens of mitochondrial enzymes governing energy production, fat oxidation, and antioxidant defense. SIRT3 is the only sirtuin with variants robustly linked to human longevity across multiple studies.

The rs11555236 variant sits in intron 5 of SIRT3, near a variable number tandem repeat (VNTR) enhancer³³ variable number tandem repeat (VNTR) enhancer
A VNTR is a region of DNA where a short sequence is repeated a variable number of times. When this repeat region acts as an enhancer, it boosts transcription of nearby genes that controls SIRT3 transcription. The A allele (reported as "T" in papers using minus-strand notation) is the protective allele: carriers show measurably higher SIRT3 protein levels, which translates to more active mitochondrial deacetylase activity.

The Mechanism

The SIRT3 intron 5 VNTR contains repeat units of 72 base pairs. A critical T-to-C transition within the second repeat of each VNTR unit determines whether a GATA2 transcription factor⁴⁴ GATA2 transcription factor
GATA2 is a zinc finger transcription factor that binds specific DNA sequences and recruits the RNA polymerase machinery to activate gene transcription binding site is present or absent. Bellizzi et al. and subsequent work by Bellizzi D et al.⁵⁵ Bellizzi et al. and subsequent work by Bellizzi D et al.
Identification of GATA2 and AP-1 Activator Elements within the Enhancer VNTR Occurring in Intron 5 of the Human SIRT3 Gene. Mol Cells, 2009 demonstrated that GATA2 and c-Jun/c-Fos (AP-1) factors bind cooperatively to the repeat unit in an allele-specific manner, boosting SIRT3 transcription additively. The allele associated with the C genotype at rs11555236 (reported as G in papers, indicating the minus-strand C reference allele) has diminished enhancer activity; the A allele (minus-strand T) preserves the GATA binding site and drives higher SIRT3 expression.

With higher SIRT3 activity, several downstream processes are enhanced: SIRT3 deacetylates and activates SOD2 (superoxide dismutase 2), the primary mitochondrial superoxide scavenger; it deacetylates LCAD (long-chain acyl-CoA dehydrogenase), accelerating fat oxidation during fasting; and it activates FOXO3a within the mitochondrial matrix, promoting transcription of stress-resistance genes.

The Evidence

The most direct human evidence comes from the Treviso Longeva (TRELONG) prospective study⁶⁶ Treviso Longeva (TRELONG) prospective study
Albani D et al. Modulation of human longevity by SIRT3 single nucleotide polymorphisms in the prospective study "Treviso Longeva (TRELONG)." Age (Dordr), 2014, which followed 549 Italian elderly participants (age ≥70) for 7 years. In longitudinal mortality analysis, the hazard ratio for death was 0.58 for AA homozygotes versus CC homozygotes — a 42% reduction in mortality risk. Critically, this association was significant only in women (p=0.03), with no significant effect in men (p=0.52). Western blotting confirmed that AA homozygotes had significantly elevated SIRT3 protein in peripheral blood mononuclear cells compared to CC carriers, establishing the functional link between genotype and expression.

Earlier work by Bellizzi et al.⁷⁷ Bellizzi et al.
A novel VNTR enhancer within the SIRT3 gene, a human homologue of SIR2, is associated with survival at oldest ages. Genomics, 2005 found that the VNTR allele completely lacking enhancer activity was virtually absent in males older than 90, suggesting selection pressure in extreme aging. The related SNP rs4980329 was associated with longevity in the same TRELONG cohort.

At the cellular level, Hirschey et al.⁸⁸ Hirschey et al.
SIRT3 regulates mitochondrial fatty-acid oxidation by reversible enzyme deacetylation. Nature, 2010 showed that SIRT3 knockout mice developed hallmarks of fatty-acid oxidation disorders during fasting — reduced ATP, cold intolerance, and accumulation of acylcarnitines — establishing SIRT3's essential role in metabolic flexibility. A breast cancer association study⁹⁹ breast cancer association study
Yadav Payavula H et al. VNTR Polymorphism in the Intron 5 of SIRT3 and Susceptibility to Breast Cancer. Asian Pacific J Cancer Prevention, 2023 found the no-repeat allele (OR 2.67, 95% CI 1.54-4.65) significantly over-represented in breast cancer cases, further supporting the functional importance of this enhancer region.

Evidence level is moderate: the longevity data are replicated but limited to Italian cohorts; the gender-specific effect requires independent validation.

Practical Implications

SIRT3 activity is tightly coupled to cellular NAD⁺ availability. This creates a leverage point: supplementing with NAD⁺ precursors — particularly nicotinamide mononucleotide (NMN) or nicotinamide riboside (NR) — provides more substrate for SIRT3's deacetylase activity regardless of genotype, but may be especially relevant for CC carriers who have lower baseline SIRT3 expression. Fasting, caloric restriction, and ketogenic dietary patterns all raise the NAD⁺/NADH ratio, similarly boosting SIRT3 function. A ketogenic diet study¹⁰¹⁰ ketogenic diet study
Hasan-Olive MM et al. A Ketogenic Diet Improves Mitochondrial Biogenesis and Bioenergetics via the PGC1α-SIRT3-UCP2 Axis. Neurochemical Research, 2019 found upregulation of SIRT3 via the PGC1α axis.

For CC homozygotes, the combination of lower SIRT3 expression and the role of SIRT3 in activating SOD2 (mitochondrial antioxidant) means that their SOD2 may be chronically under-activated — making SOD2 genotype (rs4880) relevant context for their total mitochondrial antioxidant capacity.

Interactions

The most important interaction partner is SOD2 (rs4880). SIRT3 is the primary activator of SOD2 through deacetylation: without adequate SIRT3, SOD2 remains in its acetylated, less-active state. A CC carrier at rs11555236 (lower SIRT3) who also carries the SOD2 Val allele (rs4880, reduced mitochondrial import) faces a compounded mitochondrial antioxidant deficit — lower SIRT3 expression means reduced activation of an already-reduced-capacity SOD2 enzyme. The combined recommendation for CC + SOD2 AA/AG individuals would emphasize aggressive mitochondrial antioxidant support (ubiquinol CoQ10, manganese, selenium) and NAD⁺ precursor supplementation.

FOXO3 (rs2802292) is a second interaction point: SIRT3 and FOXO3a form a functional complex in mitochondria that regulates the transcription of mitochondrial genes under caloric restriction. Both the SIRT3 A allele (rs11555236) and the FOXO3 G allele (rs2802292) are associated with longevity, and they operate through partially overlapping pathways — SIRT3 activating FOXO3 within mitochondria, FOXO3 upregulating SIRT3 transcription in response to stress. Carriers of protective alleles at both loci likely show synergistic benefits from caloric restriction and NAD⁺-boosting interventions.

Every cell in your body can burn glucose for energy, but most tissues — especially the heart, skeletal muscle, and liver — rely heavily on fatty acids as a fuel source during fasting, exercise, and illness. Medium-chain fatty acids (carbon chain lengths C6–C12) are processed by a dedicated mitochondrial enzyme called medium-chain acyl-CoA dehydrogenase (MCAD), encoded by the ACADM gene. When MCAD is impaired, the body cannot mobilize stored fat efficiently during metabolic stress, and the resulting fuel shortage can cause hypoketotic hypoglycemia¹¹ hypoketotic hypoglycemia
Low blood glucose without the compensating rise in ketone bodies (the brain's alternative fuel) that normally occurs during fasting. This combination is more dangerous than simple hypoglycemia because the brain is deprived of both its primary and emergency fuel. — which, untreated, can progress to seizures, coma, or death.

The c.734C>T variant (rs121434281) substitutes a leucine for the serine at position 245 of the mature MCAD protein (p.Ser245Leu). This rare missense change was first described in 2001 and is classified as Pathogenic/Likely pathogenic in ClinVar (VCV000003598) based on 13 independent submissions from diagnostic laboratories including Invitae, GeneDx, and LabCorp.

The Mechanism

MCAD is a homotetrameric²² homotetrameric
Four identical subunits assembled into a single functional enzyme complex inside the mitochondria enzyme that sits at the first step of the beta-oxidation spiral for medium-chain fatty acids. It extracts electrons from fatty acyl-CoA substrates and transfers them to the electron transfer flavoprotein (ETF)³³ electron transfer flavoprotein (ETF)
A mitochondrial protein that shuttles electrons from several dehydrogenases (including MCAD) to the main respiratory chain. ETFA and ETFB gene variants cause a separate condition, multiple acyl-CoA dehydrogenase deficiency (MADD)., coupling fatty acid breakdown to ATP production.

Serine-245 sits within the substrate-binding region of the MCAD protein. The Ser→Leu substitution introduces a bulkier, hydrophobic side chain into a position normally occupied by a polar residue, disrupting local folding and reducing enzyme activity. Functional studies in patients⁴⁴ Functional studies in patients
Zschocke J et al. Molecular and functional characterisation of mild MCAD deficiency. Hum Genet, 2001 carrying this variant homozygously showed residual MCAD activities falling between classical MCAD deficiency (near-zero activity) and obligate heterozygotes — indicating partial, not complete, loss of function.

Because MCAD deficiency is autosomal recessive, a single copy of S245L (heterozygous carrier) does not impair fatty acid oxidation: one functional ACADM allele is sufficient for normal MCAD activity. Disease occurs only when a person inherits two pathogenic ACADM alleles — either S245L homozygous or compound heterozygous with another pathogenic variant such as the common K304E (c.985A>G) founder mutation.

The Evidence

MCAD deficiency is the most common inherited disorder of fatty acid oxidation, with overall incidence of approximately 1 in 10,000–17,000 live births in populations of northern European descent. The K304E (K329E) variant⁵⁵ The K304E (K329E) variant
Historically called K329E due to inclusion of the 20-amino-acid mitochondrial targeting sequence in older protein numbering; the mature protein numbering gives K304E. Both terms refer to the same variant. accounts for roughly 80–90% of all MCAD deficiency alleles in northern Europeans due to a founder effect⁶⁶ founder effect
A dramatic reduction in allele diversity caused by the descent of a large population from a small ancestral group, as occurred in northern European populations in which the K304E mutation became prevalent.

The S245L variant is far rarer — the T allele frequency is approximately 0.000015 in gnomAD (21 alleles in 1.4 million sequenced), consistent with an ultra-rare pathogenic allele. No homozygotes are recorded in gnomAD.

The first clinical report⁷⁷ The first clinical report
Zschocke J et al. Molecular and functional characterisation of mild MCAD deficiency. Hum Genet, 2001 identified S245L in an infant with a mildly abnormal newborn screening acylcarnitine profile who was homozygous for the mutation due to consanguinity. Urinary organic acids were completely normal, and phenylpropionic acid loading tests were normal — features consistent with a mild (not classical) MCAD deficiency phenotype with meaningful residual enzyme activity. This contrasts with classical MCAD deficiency (typically biallelic K304E), which produces striking organic aciduria and no residual activity.

Practical Actions

For heterozygous carriers, no dietary or supplemental intervention is required. The principal relevance is reproductive: if a carrier's partner also carries a pathogenic ACADM variant, each pregnancy has a 25% chance of producing an affected child.

For affected individuals (homozygous S245L or compound heterozygous with another ACADM pathogenic variant), management per GeneReviews⁸⁸ GeneReviews
Chang IJ, Lam C, Vockley J. Medium-Chain Acyl-Coenzyme A Dehydrogenase Deficiency. GeneReviews, 2024 centres on three principles: (1) strict avoidance of prolonged fasting at all ages; (2) emergency glucose supplementation during illness or surgery; and (3) avoidance of medium-chain triglyceride (MCT)-containing products, ketogenic diets, and binge alcohol consumption, all of which can trigger metabolic decompensation.

Well-managed patients with MCAD deficiency can lead entirely normal lives. The condition is routinely detected through newborn screening in most high-income countries; early identification prevents the first — often life-threatening — metabolic crisis.

Interactions

Compound heterozygosity is the most clinically important interaction for this SNP. An individual who carries S245L on one ACADM allele and the common K304E variant (c.985A>G, rs77931234) on the other will have biallelic ACADM deficiency and a clinical phenotype similar to classical MCAD deficiency. The Zschocke 2001 paper documented exactly this combination in two other patients in the same cohort (K304E + Y67H), showing that compound heterozygous individuals can have more severe biochemical findings than S245L homozygotes. Supervisors should consider a compound action for rs121434281 CT + rs77931234 AG (or other confirmed pathogenic ACADM variants) once those entries are in the catalog.

The body cannot make zinc — every microgram enters through the gut, and the ZIP4 transporter (SLC39A4)¹¹ ZIP4 transporter (SLC39A4)
ZIP4 is a member of the Zrt/Irt-like protein (ZIP/SLC39) family. It is the primary high-affinity zinc uptake transporter expressed on the apical surface of enterocytes in the duodenum and proximal jejunum — the sites of maximal dietary zinc absorption. is the molecular gate that makes that absorption possible. When both copies of SLC39A4 carry loss-of-function mutations, the gate fails, and zinc deficiency becomes severe enough to cause acrodermatitis enteropathica (AE)²² acrodermatitis enteropathica (AE)
AE (OMIM #201100) is the inherited form of severe zinc deficiency. It typically presents in infancy with a characteristic triad: periorificial and acral dermatitis, alopecia, and diarrhea. Without treatment it is fatal; with lifelong zinc supplementation, prognosis is excellent..

rs121434293 encodes the Gln278His substitution (c.834G>C, NM_017767.3) — a glutamine-to-histidine change in the transmembrane domain of ZIP4. It was classified as pathogenic by ClinVar (variation ID 18584, RCV000003723) based on OMIM curation and functional data. Heterozygous carriers have one functioning copy of ZIP4 and do not develop AE but may warrant attention in contexts of low dietary zinc intake or increased zinc demand.

The Mechanism

ZIP4 is an 8-transmembrane-domain protein expressed on the enterocyte apical membrane that actively transports luminal zinc into the cell. The protein is dynamically regulated: during zinc deficiency, ZIP4 mRNA is stabilised and surface expression increases; during zinc sufficiency, the protein is ubiquitinated and degraded, preventing toxic zinc accumulation. ³³ Küry et al. showed that AE-associated missense mutations reduce zinc uptake activity, disrupt zinc-responsive trafficking to the plasma membrane, and impair proteolytic processing of the extracellular amino-terminal domain — three distinct functional mechanisms all converging on the same phenotype.

The Gln278 residue sits within a transmembrane segment. Substitution to histidine introduces a bulkier, positively charged imidazole side chain that alters the three-dimensional conformation of the transport pore. Functional studies of analogous AE mutations demonstrate that even single amino acid changes in transmembrane residues can abolish zinc transport activity or prevent the protein from reaching the plasma membrane in a zinc-responsive manner.

The Evidence

SLC39A4 was identified as the AE gene⁴⁴ SLC39A4 was identified as the AE gene
Kury et al. Identification of SLC39A4, a gene involved in acrodermatitis enteropathica. Nature Genetics, 2002 by mutation analysis in eight affected families. All patients were either homozygous or compound heterozygous for loss-of-function variants. Since then, the mutation spectrum has expanded substantially — by the time of the 2009 mutation update⁵⁵ 2009 mutation update
Wang et al. An update on mutations of the SLC39A4 gene in acrodermatitis enteropathica. Dermatology, 2009, over 40 pathogenic variants had been catalogued across all 12 exons.

The rs121434293 G allele (Gln278His) appears in ClinVar as pathogenic, submitted by OMIM-curated records. Its population frequency is extremely rare — just one occurrence in 77,444 chromosomes from the Japanese 38KJPN cohort (G allele frequency ~0.00001). No homozygous GG individuals have been observed in population databases, consistent with the clinical severity of homozygous AE.

Treatment outcomes are excellent when zinc is replaced⁶⁶ Treatment outcomes are excellent when zinc is replaced
Alwadany et al. Acrodermatitis enteropathica: A rare case with lifelong implications. Cureus, 2023. Clinical response to high-dose oral zinc sulfate typically appears within 5–10 days. Skin lesions resolve within weeks, and with lifelong supplementation the prognosis is essentially normal.

Practical Actions

For homozygous carriers (disease state): this is a medical condition requiring immediate specialist referral, lifelong oral zinc replacement, and regular monitoring of serum zinc, copper, and alkaline phosphatase. Elemental zinc dosing starts at 3–10 mg/kg/day and is adjusted to maintenance (1–3 mg/kg/day) once zinc levels normalise. Zinc sulfate is the most widely studied formulation; zinc gluconate or acetate may be used when gastrointestinal side effects occur.

For heterozygous carriers: zinc absorption capacity is reduced on one allele. Dietary zinc intake from red meat, shellfish (especially oysters), legumes, nuts, and seeds is important, and supplementation should be considered during periods of increased demand (growth, pregnancy, illness).

Interactions

AE requires biallelic loss of function — two mutant SLC39A4 alleles are needed for disease. rs121434293 (Gln278His) can combine with any other pathogenic SLC39A4 variant (compound heterozygosity) to produce full AE. Carriers of this variant who have a partner who is also a carrier of any pathogenic SLC39A4 variant face a 25% per-pregnancy risk of an affected child — genetic counselling is indicated. Dietary zinc insufficiency (common with vegan diets or low-animal-protein diets) can lower the functional reserve in heterozygous carriers and transiently worsen zinc status.

Apolipoprotein B-100 (apoB-100) is the structural backbone of every LDL particle¹¹ LDL particle
Low-density lipoprotein: the primary cholesterol-carrying particle in blood; high levels are a major cardiovascular risk factor. Without apoB-100, the liver cannot package and export VLDL — and without VLDL, there is no LDL. The rs121918383 A allele introduces a premature stop codon at position 1333 of the protein, producing a severely truncated apoB fragment (apoB-30) that is too short to assemble into lipoprotein particles and is degraded before it reaches the bloodstream. The result is a dramatic reduction in circulating LDL cholesterol — a condition called familial hypobetalipoproteinemia (FHBL)²² familial hypobetalipoproteinemia (FHBL)
FHBL: an autosomal codominant disorder characterized by plasma LDL and apoB levels below the 5th percentile for age and sex.

The Mechanism

APOB resides on chromosome 2 and is transcribed from the minus strand. The rs121918383 A allele on the plus (forward) strand corresponds to a C→T change on the coding strand transcript (NM_000384.3:c.3997C>T), converting the codon for arginine-1333 to a stop codon (UAA). The resulting apoB-30 protein — only 30% of the full 4,536-amino-acid sequence — lacks the lipid-binding domains required for VLDL assembly and is rapidly degraded intracellularly. Truncated apoB fragments shorter than apoB-30³³ Truncated apoB fragments shorter than apoB-30
Yue et al. Novel mutations of APOB cause ApoB truncations undetectable in plasma and familial hypobetalipoproteinemia. Hum Mutat, 2002 are invariably undetectable in plasma, which means heterozygous carriers present with a single functional APOB allele producing roughly 50% of the normal apoB-100 output — and correspondingly very low LDL cholesterol.

The Evidence

This is an autosomal codominant disorder: one copy reduces LDL substantially; two copies cause severe disease. Heterozygous carriers typically have plasma LDL-C and apoB below the 5th centile for age and sex, with total cholesterol often 30–50% below population norms. A 2020 meta-analysis of 12 case-control studies⁴⁴ A 2020 meta-analysis of 12 case-control studies
Welty FK. Hypobetalipoproteinemia and abetalipoproteinemia: liver disease and cardiovascular disease. Curr Opin Lipidol, 2020 covering 57,973 individuals found that APOB protein-truncating variants confer a 72% reduction in coronary heart disease risk (OR 0.28, 95% CI 0.12–0.64) — making this one of the strongest single-gene cardiovascular protective effects in the human genome.

Heterozygous carriers are usually asymptomatic. A minority develop hepatic steatosis⁵⁵ hepatic steatosis
Fatty liver: impaired hepatic lipid export due to reduced VLDL assembly causes triglycerides to accumulate in liver cells from impaired hepatic lipid export; this rarely progresses to steatohepatitis or cirrhosis. Burnett, Hooper, and Hegele's GeneReviews chapter⁶⁶ Burnett, Hooper, and Hegele's GeneReviews chapter
Burnett JR et al. APOB-Related Familial Hypobetalipoproteinemia. GeneReviews, 2021 estimates 5–10% of heterozygotes develop clinically significant liver dysfunction.

The extremely rare homozygous state (both APOB alleles non-functional) mimics abetalipoproteinemia⁷⁷ abetalipoproteinemia
A severe disorder with complete absence of apoB-containing lipoproteins, causing fat malabsorption and fat-soluble vitamin deficiencies from birth and requires intensive clinical management from infancy.

Practical Actions

For heterozygous carriers, the primary clinical implication is cardiovascular protection from very low LDL — but liver surveillance is warranted because of the hepatic steatosis risk. Periodic liver function tests and liver imaging can catch early steatohepatitis before it progresses. A 2006 study⁸⁸ 2006 study
Clarke et al. Assessment of tocopherol metabolism and oxidative stress in familial hypobetalipoproteinemia. Clin Chem, 2006 found that heterozygous FHBL patients have lower absolute vitamin E levels, but when corrected for the low lipid-carrier concentration, tissue tocopherol status is normal — routine vitamin E supplementation is NOT indicated for heterozygotes. Dietary fat restriction is not necessary for heterozygotes. Dietary choices that support liver health (limiting excess fructose, alcohol, and ultra-processed foods) are especially relevant given the hepatic steatosis risk.

Biallelic carriers (homozygotes) require specialist management: high-dose fat-soluble vitamins (vitamins A, D, E, K), dietary fat restriction (<30% of calories), and regular neurological, ophthalmological, and hepatic surveillance. These individuals should be under care of a metabolic disease specialist.

Interactions

rs121918383 shares the same disease mechanism with other APOB truncating variants including rs121918384 (Val1856fs frameshift). Carriers of truncating mutations in APOB in combination with APOE genotype (rs429358/rs7412) show variable LDL levels — APOE ε4 carriers with FHBL may have higher LDL than expected from the truncating mutation alone, while ε2 carriers may have even lower LDL.

Blood clots when you need them to; the rest of the time, a network of natural anticoagulants keeps coagulation in check. Protein S — encoded by the PROS1 gene — is one of those brakes. It acts as a cofactor for activated protein C (APC)¹¹ activated protein C (APC)
APC cleaves and inactivates coagulation Factors Va and VIIIa, shutting down the amplification loop that generates thrombin, the enzyme that forms blood clots. Without sufficient protein S, APC cannot do its job efficiently, and coagulation goes unrestrained. rs121918475 — known as the Q279X or p.Gln279Ter variant — introduces a premature stop codon²² premature stop codon
CAG (glutamine) is changed to TAG (stop) at amino acid position 279 of the canonical PROS1 isoform; position 311 in the longer isoform at a site well before the protein's functional C-terminus, producing a severely truncated, non-functional protein. This is a pathogenic, well-characterized cause of hereditary protein S deficiency.

The Mechanism

PROS1 encodes a 676-amino-acid vitamin K–dependent plasma glycoprotein. The Q279X variant truncates the protein at position 279, eliminating the two Laminin G-like domains³³ Laminin G-like domains
Laminin G domains mediate the interaction between protein S and APC, as well as protein S's direct role in inhibiting Factor Xa and Factor Va independently of APC in the C-terminus that are essential for APC cofactor activity. The truncated product — if it is even stably expressed — retains no meaningful anticoagulant function.

Because Q279X is a stop-gain variant, the truncated transcript also undergoes nonsense-mediated mRNA decay (NMD)⁴⁴ nonsense-mediated mRNA decay (NMD)
A cellular surveillance mechanism that degrades mRNA molecules with premature stop codons to prevent synthesis of aberrant proteins in most mammalian cells, meaning protein S output from the affected allele may be near zero. The result in heterozygotes is typically a Type I protein S deficiency: plasma levels of total protein S antigen, free protein S antigen, and protein S activity are all reduced to roughly 40–60% of normal — consistent with the population-level measurement of 48% of normal in high-risk PROS1 variant carriers from the 2025 UK Biobank study⁵⁵ 2025 UK Biobank study
Chaudhry et al. measured total protein S levels in carriers of high-risk PROS1 variants (functional impact score = 1.0) across 426,436 UK Biobank participants.

The Evidence

This variant has the highest tier of clinical evidence: it is classified Pathogenic in ClinVar (OMIM 176880.0007), it has been confirmed through direct PROS1 mutational screening in affected families, and it is curated by the OMIM-Curated Records review panel. The Q279X change has been documented in multiple independent families and confirmed by haplotype analysis⁶⁶ haplotype analysis
Hurtado et al. showed that Q279X arises on more than one haplotype background, indicating it has occurred as a recurrent de novo mutation rather than descending from a single founder, establishing it as a recurrent pathogenic variant rather than a population-specific founder mutation.

At the population scale, a 2025 JAMA study of 630,000 biobank participants⁷⁷ 2025 JAMA study of 630,000 biobank participants
Chaudhry, Haj, Ryu et al., published April 2025 in JAMA, combining UK Biobank (426,436) and All of Us (204,006) cohorts found that carriers of high-risk PROS1 variants — loss-of-function alleles with a functional impact score of 1.0, in the same tier as Q279X — face an adjusted odds ratio of 14.01 (95% CI 6.98–27.14, P = 9.09 × 10⁻¹¹) for venous thromboembolism, making it one of the strongest single-gene thrombophilia risk factors quantified in unselected population cohorts.

For pregnancy specifically⁸⁸ pregnancy specifically
Croles et al. 2017 meta-analysis of 36 observational studies covering all major thrombophilias during pregnancy, protein S deficiency raises the absolute postpartum VTE risk to 4.2% (95% CrI 0.7–9.4%). In women using combined oral contraceptives⁹⁹ women using combined oral contraceptives
Van Vlijmen et al. 2016 systematic review and meta-analysis; "severe" thrombophilias defined as antithrombin, protein C, or protein S deficiency, VTE risk rises to an absolute rate of 4.3–4.6 per 100 pill-years — a level at which guidelines uniformly recommend against combined hormonal contraceptive use.

The 2023 American Society of Hematology guidelines on thrombophilia testing¹⁰¹⁰ thrombophilia testing
Middeldorp et al., Blood Advances 2023 conditionally recommend testing first-degree relatives of known protein S deficiency carriers before starting combined hormonal contraceptives or other thrombosis-promoting therapies, and before pregnancy.

Practical Implications

A Q279X carrier faces three categories of actionable risk. First, protein S levels should be confirmed by laboratory testing — plasma total and free protein S antigen plus protein S activity — both to quantify the deficiency and to document it for medical providers. Second, situations that further activate the coagulation system (combined hormonal contraceptives, surgery, immobility, pregnancy, postpartum period) carry acutely elevated thrombosis risk that is quantifiable and in most cases preventable with appropriate prophylaxis. Third, thrombosis events themselves may require longer anticoagulation than in non-carriers, since the underlying coagulation imbalance persists after an acute event.

For anticoagulation after a VTE event, full-dose DOACs (rivaroxaban, apixaban)¹¹¹¹ full-dose DOACs (rivaroxaban, apixaban)
Kovac et al. 2024 ISTH SSC communication; hazard ratios for recurrent VTE on full-dose DOACs ranged from 0.3 to 0.75 in cohort studies; low-dose DOACs were not assessed in severe thrombophilia and should be avoided appear comparable to warfarin in severe thrombophilia, with caution against reduced-dose ("half-tablet") regimens due to insufficient evidence.

Interactions

The most clinically important interaction is with Factor V Leiden (rs6025, F5 R506Q)¹²¹² Factor V Leiden (rs6025, F5 R506Q)
Factor V Leiden is the most common inherited thrombophilia (~5% of Europeans); it creates a coagulation Factor Va molecule resistant to cleavage by APC, meaning protein S deficiency and Factor V Leiden attack the same APC-dependent pathway from different sides. A carrier of both Q279X and Factor V Leiden would face a compounded impairment of the APC anticoagulant pathway, with predicted risk exceeding either variant alone. Similarly, the prothrombin G20210A variant (rs1799963)¹³¹³ prothrombin G20210A variant (rs1799963)
Raises plasma prothrombin 30%, pushing the coagulation system toward clotting while protein S deficiency simultaneously weakens the brake would be additive with protein S deficiency on the thrombosis side of the ledger.

Acquired thrombophilic states — antiphospholipid syndrome, active malignancy, nephrotic syndrome (which causes urinary loss of protein S), pregnancy, and immobilization — all compound with Q279X in an additive or synergistic manner. Vitamin K antagonists (warfarin) paradoxically reduce protein S levels as part of their mechanism of action; this is relevant when initiating anticoagulation or managing a carrier who is perioperatively bridged.

Every cell in your body has a first line of defence against viruses before the adaptive immune system has time to respond. IFITM3¹¹ IFITM3
Interferon-Induced Transmembrane Protein 3 — a small membrane protein that acts as a physical barrier preventing enveloped viruses from fusing with endosomal membranes and entering the cell is one of the most potent of these innate antiviral sentinels. When interferon signals arrive (as they do within hours of viral exposure), IFITM3 expression surges, lining the endosomal compartments where influenza, SARS-CoV-2, Ebola, and other enveloped viruses must complete their entry. rs12252 is the most studied genetic variant in this gene — and it carries a striking population frequency divide that helps explain why some ethnic groups have been disproportionately affected by pandemic influenza.

The Mechanism

rs12252 sits at position 320,772 on chromosome 11 (GRCh38). The IFITM3 gene is transcribed from the minus strand, so papers often refer to this variant using coding-strand notation (T/C) — but in genome files, the alleles are A (reference, normal) and G (risk). The G allele corresponds to a c.42T>C substitution that is formally synonymous: both codon forms encode serine at position 14 (p.Ser14=). However, the nucleotide change sits at the first splice acceptor site²² splice acceptor site
The sequence at the 3' end of an intron that signals where to cut and join exons during mRNA processing of IFITM3's intron, and the original hypothesis proposed that the C allele disrupts splicing, producing a truncated IFITM3 protein lacking the N-terminal 21 amino acids (Δ21 IFITM3) — a region containing an endocytic sorting signal essential for correct intracellular localisation.

The exact mechanism remains actively debated. A 2017 study using RNA sequencing of primary cells from CC homozygotes³³ RNA sequencing of primary cells from CC homozygotes detected no alternatively spliced transcripts, raising questions about whether the truncated protein actually forms in vivo. An alternative explanation is that the G allele reduces total IFITM3 protein expression rather than producing a truncated isoform — functional assays in lymphoblastoid cell lines from CC individuals show substantially lower IFITM3 protein levels and far greater susceptibility to influenza A infection compared to TT homozygotes. Whatever the molecular basis, the biological and clinical consequence — reduced antiviral IFITM3 activity — is well replicated.

The Evidence

The landmark study by Everitt et al. (2012, Nature)⁴⁴ Everitt et al. (2012, Nature) used both a mouse knockout model and a human genetic association study. Mice lacking Ifitm3 developed fulminant viral pneumonia from a normally low-pathogenicity influenza strain. In hospitalised UK patients during the 2009 H1N1 pandemic, rs12252-C was significantly enriched — approximately 1 in 17 hospitalised patients carried the CC genotype versus 1 in 300 in the general British population.

The population impact became even clearer in East Asian populations. In the Zhang et al. 2013 Nature Communications study⁵⁵ Zhang et al. 2013 Nature Communications study, the CC genotype was present in 69% of Chinese patients with severe pandemic H1N1 infection versus 25% in mild cases. The population-attributable risk of severe influenza from rs12252 was estimated at 54.3% in the Chinese population — compared to just 5.4% in Northern Europeans. Because the G allele reaches ~53% frequency in East Asians (versus ~4% in Europeans), what is a rare variant in Europe becomes a common variant in East Asia, with enormous implications for population-level susceptibility.

A 2015 meta-analysis⁶⁶ 2015 meta-analysis pooling 4 studies (445 influenza patients, 3,396 controls) confirmed: the C allele confers OR 2.70 (95% CI 1.86–3.94) for severe influenza specifically. A second independent meta-analysis in 2015 (PMID 25942469)⁷⁷ meta-analysis in 2015 (PMID 25942469) reached similar conclusions across susceptibility and severity outcomes.

For COVID-19, early Chinese cohort data showed the CC genotype was associated with more severe disease in an age-dependent manner. A 2022 meta-analysis (PMID 35461906)⁸⁸ 2022 meta-analysis (PMID 35461906) found odds ratios of 1.65–5.88 across multiple genetic models for COVID-19 susceptibility and severity. Results across individual cohorts have been mixed — several European cohorts found no significant association, likely because the G allele is too rare there to detect effects in small studies. The evidence is most consistent in East Asian and African-ancestry populations where the allele is common enough to generate statistical power.

IFITM3 also restricts Ebola virus, dengue, HIV, and West Nile virus entry in cell culture, though population genetic association data for rs12252 and these infections are limited compared to the influenza and COVID-19 literature.

Practical Actions

For individuals carrying one or two G alleles, the primary implication is respiratory virus risk management. Annual influenza vaccination takes on heightened importance: the mechanism of rs12252 risk is about viral entry and early innate defence, which is precisely what vaccination bypasses by generating adaptive immunity before exposure. COVID-19 vaccination similarly converts an innate immunity deficit into an adaptive immunity advantage.

Antiviral medications (oseltamivir for influenza, antivirals for COVID-19) act on viral replication — a distinct step downstream of IFITM3 function — and their benefit is not impaired by this variant. This means GG individuals benefit at least as much as others from early antiviral treatment if they develop influenza or COVID-19 symptoms.

Interactions

rs34481144 is the second major functional variant in IFITM3 — a regulatory SNP in the promoter that modulates IFITM3 expression levels. Haplotype studies show that the combination of rs12252 G allele and rs34481144 risk haplotype tracks with COVID-19 mortality ratios across ethnic groups in England better than either SNP alone. The two variants should be interpreted together when full IFITM3 haplotype information is available.

rs3764880 (IFITM3 coding variant) and rs3775291 (TLR3) are in nearby antiviral pathway genes. Combined defects in TLR3-interferon signalling and IFITM3 viral restriction could theoretically compound respiratory virus severity, but direct interaction data for rs12252 with these specific variants are not yet published.

The luteinizing hormone/choriogonadotropin receptor (LHCGR) is the gateway through which LH and hCG direct ovulation, corpus luteum function, and ovarian steroidogenesis. The Asn291Ser variant — a single amino acid change at position 291 from asparagine (N) to serine (S) — lies in exon 10, encoding the extracellular ligand-binding domain. Unlike its neighboring variant at position 312 (rs2293275, also in LHCGR exon 10), this variant is rare in most populations: the C allele (Ser291) reaches about 5.6% in Europeans but is nearly absent in East Asian populations (0.01%). For the small fraction of women carrying this allele, the functional consequence is increased receptor sensitivity — a property with measurable implications for ovarian stimulation and reproductive outcomes.

The Mechanism

LHCGR is a G protein-coupled receptor¹¹ G protein-coupled receptor
Receptors that activate intracellular signaling cascades via G proteins when bound by hormone ligands. LH binding activates Gs proteins, stimulating adenylyl cyclase to produce cAMP, which in turn drives follicular maturation, ovulation, and steroid synthesis in ovarian theca and granulosa cells.

Asparagine at position 291 (encoded by the T allele on the plus strand) is a candidate site for N-linked glycosylation — a sugar modification that affects protein folding, cell-surface trafficking, and receptor sensitivity. Serine (encoded by C) cannot accept N-linked glycosylation at this position. In vitro transfection studies²² In vitro transfection studies
Piersma et al. Polymorphic variations in exon 10 of the luteinizing hormone receptor. Mol Cell Endocrinol, 2007 revealed that the 291Ser variant (C allele) displays altered glycosylation status and increased receptor sensitivity relative to the wild-type 291Asn (T allele). This gain-of-function property means that cells expressing the Ser variant respond to lower concentrations of LH and achieve greater downstream cAMP signaling per unit of hormone.

The Evidence

IVF ovarian stimulation response. A 2023 prospective multicenter study of 94 normogonadotropic women undergoing IVF³³ A 2023 prospective multicenter study of 94 normogonadotropic women undergoing IVF
Alviggi et al. Genes (Basel), 2023 genotyped eight gonadotropin receptor polymorphisms and measured ovarian stimulation outcomes. Women homozygous for the T allele (TT, Asn/Asn) retrieved fewer fertilized oocytes than heterozygous C/T carriers (p=0.035), and fewer mature oocytes (p=0.05). When the rs12470652 C allele was combined with specific FSHR variants (FSHR-29 rs1394205 G allele and FSHR rs6166 G allele), the FSH dose-to-oocyte ratio increased by 5.44-fold (95% CI: 3.18–7.71, p<0.001), signaling markedly worse ovarian response in this combined genotype group.

PCOS association. A 2022 case-control study of 743 women (421 PCOS, 322 controls) from Punjab, India⁴⁴ A 2022 case-control study of 743 women (421 PCOS, 322 controls) from Punjab, India
Singh et al. BMC Endocrine Disorders, 2022 found the mutant C allele conferred a 2.3-fold risk toward PCOS progression. However, a 2025 meta-analysis⁵⁵ a 2025 meta-analysis
Singh et al. Journal of Assisted Reproduction and Genetics, 2025 examining multiple LHCGR variants across multiple studies found rs12470652 did not show statistically significant association with PCOS in any genetic model overall, suggesting the single-study finding may be population-specific.

Male fertility. Simoni et al. 2008 (n=826 European men)⁶⁶ Simoni et al. 2008 (n=826 European men)
Pharmacogenet Genomics, 2008 found that neither the N291S variant nor the insLQ variant showed differential distribution between men with maldescended testes, infertile men, and controls, indicating these functional variants do not strongly predispose to cryptorchidism or male infertility in European populations. An earlier 2002 study⁷⁷ 2002 study
Mongan et al. Eur J Endocrinol, 2002 found homozygosity for TT (N291) was modestly more frequent in undermasculinised males (p=0.05), with the combination of TT genotype and absence of the S312 allele yielding an OR of 3.28 (95% CI 1.33–8.08) for undermasculinisation — though this finding has not been replicated at scale.

The overall evidence picture is one of a variant with clear molecular function (increased receptor sensitivity) but modest and population-variable clinical associations. The IVF stimulation data is the most actionable finding, particularly for women combining rs12470652 carrier status with specific FSHR variants.

Practical Implications

The C allele is rare enough (global frequency ~5%) that most people carry two T alleles (wild-type). For the minority carrying one or two C alleles, the main clinically actionable context is IVF or other forms of ovarian stimulation. The increased receptor sensitivity suggests that C allele carriers may respond differently to exogenous LH during controlled ovarian stimulation — their receptors are more easily activated, which may alter optimal gonadotropin dosing.

For C allele carriers concerned about PCOS, the evidence is currently inconsistent across populations and should not be interpreted as a strong PCOS risk signal without corroborating clinical findings.

Interactions

rs2293275 (LHCGR N312S): The most relevant interaction is with the adjacent exon 10 variant at position 312. Both N291S and N312S affect glycosylation sites in the same extracellular domain, and both increase receptor sensitivity. Carriers of both functional variants (rs12470652 C allele + rs2293275 T allele) may have a cumulative alteration in receptor sensitivity that exceeds either variant alone. The functional literature treats these as independent glycosylation site changes with additive potential, though formal combined-effect clinical data is limited.

rs6166 (FSHR N680S): The Alviggi 2023 study specifically demonstrated that the interaction between rs12470652 C allele and FSHR variants (rs1394205 and rs6166) creates a distinct poor-ovarian-response phenotype with 5.44-fold higher FSH dose requirement. This makes FSHR genotyping highly relevant for rs12470652 C allele carriers undergoing IVF.